FUJIFILM Biotechnologies, a prominent contract development and manufacturing organization (CDMO), is currently executing a monumental expansion strategy, with approximately $7…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
Eli Lilly has significantly bolstered its position in the competitive metabolic disease landscape with detailed Phase 3 results for its…
Read More
CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
AustinPx, a Texas-based Contract Development and Manufacturing Organization (CDMO) specializing in bioavailability enhancement, has forged an exclusive agreement with Thermo…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
A new era in therapeutic innovation is dawning, marked by the successful Phase IIa clinical trial results for Hybridopa, an…
Read More
As Cell Therapies Scale and CDMOs Cut Staff, Process Know-How Is Often Getting Lost in Tech Transfer
The biopharmaceutical industry is grappling with a critical challenge: the silent erosion of invaluable "tacit knowledge" during technology transfer processes.…
Read More
What if psilocybin works about as well for depression as an SSRI?
Emerging data from recent studies and meta-analyses suggest that the highly anticipated efficacy of classic psychedelics, particularly psilocybin, in treating…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The therapeutic landscape for glucagon-like peptide-1 (GLP-1) receptor agonists has undergone a monumental transformation, extending far beyond its initial applications…
Read More
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
In a significant advancement for precision oncology, ConcertAI, a leading AI and real-world data company focused on cancer care, has…
Read More
The Oral GLP-1 Revolution: Unpacking the Scientific and Clinical Impact of Small Molecules
The pharmaceutical landscape for metabolic disorders, particularly Type 2 Diabetes and obesity, is undergoing a profound transformation, heralded by the…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The U.S. pharmaceutical landscape, historically characterized by higher drug prices compared to other developed nations, is undergoing a significant transformation,…
Read MoreYOU MAY HAVE MISSED
